Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. (Q54465171)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. |
scientific article |
Statements
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial (English)
Janusz Rolski
Matthieu Rupin
John Glaspy
Tommy Fornander
Jean-Paul Guastalla
Amer Sami
Eva Juhos
Robert Coleman
Manuel R Modiano
Jeferson Vinholes
Tamas Pinter
Alvaro RodrÃguez-Lescure
Bruce Colwell
Pierre Whitlock
Louise Provencher
Kara Laing
David Walde
Chris Price
Judith C Hugh
Barrett H Childs
Kimberly Bassi
Mary-Ann Lindsay
Véronique Wilson
Vincent Houé
Charles Vogel
TRIO/BCIRG 001 investigators
John Hainsworth
12 December 2012